FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> HIV vaccine | MVA-B

Vaccine could reduce HIV to 'minor infection'

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Could HIV one day be treated as nothing more than a minor infection? That's what researchers at the National Biotech Center in Madrid are hoping to eventually achieve with MVA-B, their early-stage HIV vaccine.

The vaccine contains four genes that trigger B and T lymphocytes, types of white blood cells that attack the virus and then destroy infected cells, respectively. Lead researcher Professor Mariano Esteban says the vaccine is like showing the immune system "a picture of the HIV so that it is able to recognize it if it sees it again in the future."

In a clinical trial, three-quarters of those who received the MVA-B vaccine developed antibodies against HIV after 11 months. A third of participants developed CD4+ cells while two-thirds developed CD8+ cells--both of which are types of T cells that fend off HIV. Although 92% of trial subjects developed an immune response to the vaccine, further testing is needed to determine whether that response can actually protect the body from the virus. The researchers are now planning a study to test whether MVA-B can be used as a therapeutic vaccine.

"If this genetic cocktail passes Phase II and Phase III future clinic trials, and makes it into production, in the future HIV could be compared to herpes virus nowadays," added Esteban.

- read the article from The Telegraph

Related Articles:
Study: Removing cholesterol from HIV boosts second immune response
HIV envelope protein approach elicits vaccine immune response
Inovio posts positive preclinical HIV vax results


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about HIV vaccine   MVA-B